000661 长春高新
已收盘 04-03 15:00:00
资讯
新帖
简况
长春高新:针对研发管线已建立严格研发里程碑管控与投入退出机制
新京报 · 04-04 23:00
长春高新:针对研发管线已建立严格研发里程碑管控与投入退出机制
长春高新:公司现阶段营收高、净利低的核心原因
证券之星 · 04-04 22:03
长春高新:公司现阶段营收高、净利低的核心原因
长春高新(000661)披露子公司注射用GenSci136临床试验申请获受理公告,4月3日股价下跌2.5%
证券之星 · 04-03 17:22
长春高新(000661)披露子公司注射用GenSci136临床试验申请获受理公告,4月3日股价下跌2.5%
长春高新:医药创新高投入、长周期、慢回报是行业基本规律
证券之星 · 04-03 15:27
长春高新:医药创新高投入、长周期、慢回报是行业基本规律
长春高新:公司销售费用主要用于合规学术推广、新品市场培育等
证券之星 · 04-03 15:21
长春高新:公司销售费用主要用于合规学术推广、新品市场培育等
长春高新:金赛药业薪酬支出增长与业务规模、新业务拓展、阶段性人员扩张、行业人才竞争紧密相关
证券之星 · 04-03 15:07
长春高新:金赛药业薪酬支出增长与业务规模、新业务拓展、阶段性人员扩张、行业人才竞争紧密相关
长春高新:海容酒店为康达旧改项目商业配套
证券之星 · 04-03 15:05
长春高新:海容酒店为康达旧改项目商业配套
长春高新(000661.SZ):注射用GenSci136境内生产药品注册临床试验申请获受理
智通财经 · 04-02
长春高新(000661.SZ):注射用GenSci136境内生产药品注册临床试验申请获受理
长春高新(000661.SZ):GenSci128片获美国FDA孤儿药资格认定
智通财经 · 03-24
长春高新(000661.SZ):GenSci128片获美国FDA孤儿药资格认定
长春高新:抑菌剂是多剂量制剂实现安全、经济、环保与人性化治疗的关键技术支撑
证券之星 · 03-20
长春高新:抑菌剂是多剂量制剂实现安全、经济、环保与人性化治疗的关键技术支撑
长春高新:公司将继续通过内培外引,不断做强核心团队
证券之星 · 03-20
长春高新:公司将继续通过内培外引,不断做强核心团队
“春风送岗”,长春高新区举办2026年春季人才招聘会
长春广播电视台 · 03-16
“春风送岗”,长春高新区举办2026年春季人才招聘会
长春高新最新公告:子公司GenSci128片获美国FDA孤儿药资格认定
证券之星 · 03-10
长春高新最新公告:子公司GenSci128片获美国FDA孤儿药资格认定
本周六长春高新区有大型招聘会
长春市政府网站 · 03-10
本周六长春高新区有大型招聘会
长春高新:公司会严格执行薪酬管理办法
证券之星 · 03-06
长春高新:公司会严格执行薪酬管理办法
长春高新:聚焦研发创新与临床价值
证券之星 · 03-06
长春高新:聚焦研发创新与临床价值
长春高新(000661.SZ):GenSci161注射液境内生产药品注册临床试验申请获得受理
智通财经 · 03-02
长春高新(000661.SZ):GenSci161注射液境内生产药品注册临床试验申请获得受理
长春高新儿童小阴茎新药获批临床,股价两日涨超12%
21世纪经济报道 · 02-26
长春高新儿童小阴茎新药获批临床,股价两日涨超12%
异动快报:长春高新(000661)2月25日14点45分触及涨停板
证券之星 · 02-25
异动快报:长春高新(000661)2月25日14点45分触及涨停板
长春高新(000661.SZ):GenSci141软膏境内生产药品注册临床试验申请获批准
智通财经 · 02-24
长春高新(000661.SZ):GenSci141软膏境内生产药品注册临床试验申请获批准
加载更多
公司概况
公司名称:
长春高新技术产业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-18
主营业务:
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售,辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。
发行价格:
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":84.68,"timestamp":1775199825000,"preClose":86.85,"halted":0,"volume":3713362,"delay":0,"changeRate":-0.025,"floatShares":400000000,"shares":408000000,"eps":2.351,"marketStatus":"已收盘","change":-2.17,"latestTime":"04-03 15:00:00","open":86.48,"high":86.48,"low":84.66,"amount":316000000,"amplitude":0.021,"askPrice":84.68,"askSize":32,"bidPrice":84.67,"bidSize":124,"shortable":0,"etf":0,"ttmEps":2.351,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775525400000},"marketStatusCode":5,"adr":0,"adjPreClose":86.85,"symbolType":"stock","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":95.54,"lowLimit":78.16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.54,"roa":"--","peRate":36.018715,"roe":"5.03%","epsLYR":6.42,"committee":0.5,"marketValue":34544000000,"turnoverRate":0.0093,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-04-08。","floatMarketCap":33839000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2624613896","title":"长春高新:针对研发管线已建立严格研发里程碑管控与投入退出机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2624613896","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624613896?lang=zh_cn&edition=full","pubTime":"2026-04-04 23:00","pubTimestamp":1775314800,"startTime":"0","endTime":"0","summary":"医药创新必须通过严谨临床试验验证安全有效,这是产品研发、获批上市、实现商业化的必经路径,也是构筑长期竞争力的核心基础。公司已建立严格的研发里程碑管控与投入退出机制,对达不到预期的项目及时止损,确保研发投入风险可控。目前,公司研发投入正进入阶段性成果逐步兑现与价值加速变现的新阶段,公司希望持续通过对外授权与自研管线研发突破持续发力,全面提升投入产出效率。","market":"hk","thumbnail":"https://media.bjnews.com.cn/cover/2026/04/04/5704587942702425963.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/04/04/5704587942702425963.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1775313121129480.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1775313121129480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","BK0075","BK0028","BK0057","000661","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624189656","title":"长春高新:公司现阶段营收高、净利低的核心原因","url":"https://stock-news.laohu8.com/highlight/detail?id=2624189656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624189656?lang=zh_cn&edition=full","pubTime":"2026-04-04 22:03","pubTimestamp":1775311395,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新04月04日在投资者关系平台上答复投资者关心的问题。公司相关产品被纳入2025 年国家医保药品目录,充分体现了国家医保部门对产品临床价值、创新属性及患者获益的官方认可,有利于提升产品市场渗透率、扩大销售规模与患者覆盖。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040400011219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624656761","title":"长春高新(000661)披露子公司注射用GenSci136临床试验申请获受理公告,4月3日股价下跌2.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624656761","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624656761?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:22","pubTimestamp":1775208159,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,长春高新报收于84.68元,较前一交易日下跌2.5%,最新总市值为345.44亿元。该股当日开盘86.48元,最高86.48元,最低84.66元,成交额达3.16亿元,换手率为0.93%。长春高新于2026年4月3日披露《关于子公司注射用GenSci136境内生产药品注册临床试验申请获得受理的公告》。公告显示,公司控股子公司金赛药业收到国家药品监督管理局签发的《受理通知书》,其申报的注射用GenSci136境内生产药品注册临床试验申请已获受理,拟用于治疗眼肌型重症肌无力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0046","BK0075","000661","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624653385","title":"长春高新:医药创新高投入、长周期、慢回报是行业基本规律","url":"https://stock-news.laohu8.com/highlight/detail?id=2624653385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624653385?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:27","pubTimestamp":1775201228,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新04月03日在投资者关系平台上答复投资者关心的问题。正如之前多次回复您提问中提到的费用投入和第二曲线等情况,医药创新高投入、长周期、慢回报是行业基本规律,转型投入与短期营收不匹配并非低效,而是正常阶段特征。公司坚持可控投入、精准培育,希望能够尽快拓展新的增长曲线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300024484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","000661","09939","BK0075","BK0028","BK0239","BK1161","BK0057","BK0046","BK0188","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624658732","title":"长春高新:公司销售费用主要用于合规学术推广、新品市场培育等","url":"https://stock-news.laohu8.com/highlight/detail?id=2624658732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624658732?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:21","pubTimestamp":1775200873,"startTime":"0","endTime":"0","summary":"请公司详细列出销售费用的具体去向,尤其是“市场推广费”和“咨询费”的支付对象。类似问题您已多次提问,在此再次回复您,公司销售费用主要用于合规学术推广、新品市场培育等,系医药行业特性决定。对于应披露的信息,公司会按照法律法规要求履行披露义务,具体请参见定期报告等,谢谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300024079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0057","000661","BK0046","BK0239","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624658986","title":"长春高新:金赛药业薪酬支出增长与业务规模、新业务拓展、阶段性人员扩张、行业人才竞争紧密相关","url":"https://stock-news.laohu8.com/highlight/detail?id=2624658986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624658986?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:07","pubTimestamp":1775200037,"startTime":"0","endTime":"0","summary":"请问金赛药业贡献了公司绝大部分利润,但在利润下滑期,为何员工薪酬不仅不压缩反而逆势上涨?金赛药业作为公司核心经营主体,薪酬支出增长与业务规模、新业务拓展、阶段性人员扩张、行业人才竞争紧密相关,并非利润下滑就简单一刀切降薪,不存在通过薪酬转移利润、损害公司利益的情形,谢谢!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300023758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0046","BK0028","BK0075","000661","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624658683","title":"长春高新:海容酒店为康达旧改项目商业配套","url":"https://stock-news.laohu8.com/highlight/detail?id=2624658683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624658683?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:05","pubTimestamp":1775199924,"startTime":"0","endTime":"0","summary":"半年报显示海容酒店管理公司新增占用资金2450万。海容酒店为多年前康达旧改项目整体规划的一部分,旨在完善康达旧改项目等商业配套、提升项目竞争力、助力库存去化,半年报显示的2450 万为与相关酒店管理子公司的经营性资金往来,不存在非经营性占用、更无利益输送。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300023706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","BK0057","000661","BK0075","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624357769","title":"长春高新(000661.SZ):注射用GenSci136境内生产药品注册临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2624357769","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624357769?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:43","pubTimestamp":1775123036,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司控股子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》,金赛药业注射用GenSci136的境内生产药品注册临床试验申请获得受理。注射用GenSci136是金赛药业自主研发的一款治疗用生物制品1类药物,拟用于治疗眼肌型重症肌无力(oMG)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0075","BK0057","BK0046","BK0028","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621068734","title":"长春高新(000661.SZ):GenSci128片获美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068734","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621068734?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:39","pubTimestamp":1774345154,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到美国食品药品监督管理局(简称“FDA”)通知,授予GenSci128片孤儿药资格认定,用于胃癌的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LABU","BK0188","BK0028","BK0057","BK4588","000661","BK0046","BK4585","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620203784","title":"长春高新:抑菌剂是多剂量制剂实现安全、经济、环保与人性化治疗的关键技术支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620203784?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:45","pubTimestamp":1773999910,"startTime":"0","endTime":"0","summary":"请问公司有没有没有添加苯酚抑菌剂的产品?同时我看到公司持续投入高额研发管理费用,为什么现在公司没有研发出来未添加苯酚抑菌剂的生长激素和同行进行竞争呢?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000031238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0075","BK0057","BK0046","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620360789","title":"长春高新:公司将继续通过内培外引,不断做强核心团队","url":"https://stock-news.laohu8.com/highlight/detail?id=2620360789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620360789?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:39","pubTimestamp":1773995952,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)03月20日在投资者关系平台上答复投资者关心的问题。投资者提问:公司是否考虑过从一些优秀的同行公司招聘一些真正懂研发懂管理懂销售的人才来带领公司的研发、销售、和日常管理? 比如优秀的同行业公司,特宝生物,安科生物等。长春高新回复:您好,公司虽为相关行业龙头企业,但始终保持开放进取心态,高度重视人才队伍建设,坚持市场化引才思路,公司将继续通过内培外引,不断做强核心团队,以高素质人才支撑公司高质量发展,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000028380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","BK0075","000661","BK0046","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619007439","title":"“春风送岗”,长春高新区举办2026年春季人才招聘会","url":"https://stock-news.laohu8.com/highlight/detail?id=2619007439","media":"长春广播电视台","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619007439?lang=zh_cn&edition=full","pubTime":"2026-03-16 13:31","pubTimestamp":1773639060,"startTime":"0","endTime":"0","summary":"3月14日,长春高新区“才聚高新 创享未来”2026年春季人才招聘会在中商·世界里购物中心举行。作为长春新区产业发展与科技创新的核心引擎,长春高新区始终坚持“发展是第一要务,人才是第一资源”的理念。本次春季招聘大会,既是高新区落实“人才强区”战略、服务企业、稳定就业的务实之举,也是构建人才与企业直接对话、助力人才扎根高新、建功立业的关键平台。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-16/doc-inhreeev8883258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0057","BK0028","BK0046","BK0188","000661","BK0239","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618939437","title":"长春高新最新公告:子公司GenSci128片获美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939437","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618939437?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:10","pubTimestamp":1773137428,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司子公司金赛药业收到美国FDA通知,GenSci128片获孤儿药资格认定,用于治疗胰腺癌。该药品为治疗用化药1类新药,针对TP53 Y220C突变的选择性重激活剂。获得孤儿药资格认定有助于GenSci128片在美国的后续研发和审评过程中获得政策支持,包括临床试验费用的税收抵免、免除新药申请费等。但医药产品具有高风险、高附加值特点,临床试验进程存在不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000030594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0028","BK0046","BK0188","000661","BK0239","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618836869","title":"本周六长春高新区有大型招聘会","url":"https://stock-news.laohu8.com/highlight/detail?id=2618836869","media":"长春市政府网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618836869?lang=zh_cn&edition=full","pubTime":"2026-03-10 12:34","pubTimestamp":1773117240,"startTime":"0","endTime":"0","summary":"转自:长春发布@正在找工作的你金三银四招聘季,春风行动送岗来!不想奔波找工作?不想盲目海投无回应?想要家门口的优质岗、有保障的好工作?别犹豫,看这里!👇👇👇长春高新区2026年春季人才招聘大会重磅来袭!100+优质企业!3000+空缺岗位!企业直招、实时选岗、政策解读、就业指导...助你在这个春天,斩获心仪offer,✨ 奔赴美好前程!✨来 源:长春高新人才编 辑:刘素娜\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-10/doc-inhqnrqu0111881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0239","BK0075","BK0057","BK0046","BK0028","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617689175","title":"长春高新:公司会严格执行薪酬管理办法","url":"https://stock-news.laohu8.com/highlight/detail?id=2617689175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617689175?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:39","pubTimestamp":1772789954,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)03月06日在投资者关系平台上答复投资者关心的问题。投资者提问:公司多次回复称“深化费用精细化管控” ,但从2025年业绩预告来看,费用端依然严重侵蚀利润。投资者看到的是公司赚钱管理层花,一分不留给股东 。请问面对濒临亏损的局面,2026年管理层工资薪酬是否愿意与净利润增幅挂钩,与中小股东共渡难关?长春高新回复:您好,公司会严格执行薪酬管理办法,实现薪酬分配与公司业绩考核评价的有机结合,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600028812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0188","BK0239","BK0046","BK0057","000661","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617686299","title":"长春高新:聚焦研发创新与临床价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2617686299","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617686299?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:30","pubTimestamp":1772789437,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新03月06日在投资者关系平台上答复投资者关心的问题。具体新产品及在研产品情况可参见公司相关公告,谢谢!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600028511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0046","BK0028","BK0075","000661","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616838438","title":"长春高新(000661.SZ):GenSci161注射液境内生产药品注册临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2616838438","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616838438?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:38","pubTimestamp":1772440714,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布公告,近日,公司控股子公司——长春金赛药业有限责任公司(以下简称“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》,金赛药业GenSci161注射液的境内生产药品注册临床试验申请获得受理。GenSci161注射液可同时靶向关键促炎细胞因子白细胞介素-1(IL-1)的两种亚型——IL-1α和IL-1β,有望抑制下游炎症信号通路的激活,为中重度患者提供新的长期系统治疗选择。目前,GenSci161注射液已在临床前动物模型中表现出良好的疗效,展现出治疗子宫内膜异位症及化脓性汗腺炎的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ):GenSci161注射液境内生产药品注册临床试验申请获得受理","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK0239","BK0075","000661","BK0046","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614703094","title":"长春高新儿童小阴茎新药获批临床,股价两日涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614703094","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614703094?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:04","pubTimestamp":1772089440,"startTime":"0","endTime":"0","summary":" 2月25日,长春高新以涨停收盘,报97.26元/股,收获2026年开年以来首个涨停;2月26日公司股价持续上行,截至14:30左右,报100元/股,涨幅2.82%,总市值达408亿元,股价两日累计涨超12%。 据财联社报道,长春高新证券部公司人士回应称,该产品当前仅获批开展此前公告所述临床试验,适应症需严格按照批件执行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-26/doc-inhpcqkk7304859.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-26/doc-inhpcqkk7304859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","000661","BK0046","BK0239","BK0075","BK0057","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614708896","title":"异动快报:长春高新(000661)2月25日14点45分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2614708896","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614708896?lang=zh_cn&edition=full","pubTime":"2026-02-25 14:45","pubTimestamp":1772001922,"startTime":"0","endTime":"0","summary":"证券之星2月25日盘中消息,14点45分长春高新触及涨停板。其所属行业生物制品目前上涨。领涨股为三生国健。该股为疫苗,阿尔茨海默病,振兴东北概念热股,当日疫苗概念上涨1.48%,阿尔茨海默病概念上涨1.33%,振兴东北概念上涨1.28%。2月24日的资金流向数据方面,主力资金净流出336.47万元,占总成交额1.23%,游资资金净流入573.18万元,占总成交额2.1%,散户资金净流出236.72万元,占总成交额0.87%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500018219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0028","BK0046","BK0239","BK0188","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613679465","title":"长春高新(000661.SZ):GenSci141软膏境内生产药品注册临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613679465","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613679465?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:53","pubTimestamp":1771926838,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,金赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准。该药品适应症:用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ):GenSci141软膏境内生产药品注册临床试验申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0075","BK0057","BK0046","BK0028","000661"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775412344943,"stockEarnings":[{"period":"1week","weight":-0.0213},{"period":"1month","weight":-0.0485},{"period":"3month","weight":-0.085},{"period":"6month","weight":-0.3486},{"period":"1year","weight":-0.1491},{"period":"ytd","weight":-0.085}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.0496},{"period":"3month","weight":-0.0224},{"period":"6month","weight":-0.0007},{"period":"1year","weight":0.161},{"period":"ytd","weight":-0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"104055人(较上一季度减少4.63%)","perCapita":"3840股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售,辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}